微芯生物：预计2025年年度净利润为5346万元左右

Group 1 - The company Microchip Biotech expects to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168 million yuan compared to the same period last year, thus turning a profit [1] - The significant change in performance is attributed to the product Sigleptin's unique clinical value in "diabetes and liver management," along with efforts in self-operated, strategic partnerships, and new retail channels, resulting in a sales revenue increase of approximately 123% year-on-year [1] - The product Sidabenamine has gained support from the National Healthcare Security Administration and market recognition, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Catalog in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]